A Phase I Escalating Dose Ranging Study to Evaluate the Safety and Immunogenicity of the VAX128 A, B, and C Novel H1N1 Influenza Vaccine Constructs in Healthy Adults 18-49 Years of Age and in Community Living Adults greater than or equal to 65 Years of Age.

Trial Profile

A Phase I Escalating Dose Ranging Study to Evaluate the Safety and Immunogenicity of the VAX128 A, B, and C Novel H1N1 Influenza Vaccine Constructs in Healthy Adults 18-49 Years of Age and in Community Living Adults greater than or equal to 65 Years of Age.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jul 2012

At a glance

  • Drugs VAX 128 (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Mar 2011 Status changed from recruiting to completed.
    • 14 Aug 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top